One such example for patients with HER2+, HR+ breast cancer, the monarchHER trial, was a phase 2 clinical trial examining the efficacy of abemaciclib with either the humanized HER2 antibody trastuzumab alone, or a combination of trastuzumab and fulvestrant, compared with standard-of-care treatment. The gene discussed is ERBB2; the disease is breast cancer.